Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

sight sciences inc - SGHT

SGHT

Close Chg Chg %
9.09 -0.10 -1.10%

Closed Market

8.99

-0.10 (1.10%)

Volume: 340.87K

Last Updated:

Oct 23, 2026, 4:00 PM EDT

Trade Now

Company Overview: sight sciences inc - SGHT

SGHT Key Data

Open

$8.87

 Day Range

8.87 - 9.26

52 Week Range

3.38 - 9.71

 Market Cap

$479.27M

Shares Outstanding

55.09M

 Public Float

35.88M

Beta

2.45

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.56

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

350.24K

  

SGHT Performance

1 Week
 
 8.57%
 
1 Month
 
 0.67%
 
3 Months
 
 83.10%
 
1 Year
 
 70.27%
 
5 Years
 
 -66.67%
 

SGHT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About sight sciences inc - SGHT

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

SGHT At a Glance

Sight Sciences, Inc.
4040 Campbell Avenue
Menlo Park, California 94025
Phone 1-877-266-1144 Revenue 77.36M
Industry Medical Specialties Net Income -38,426,000.00
Sector Health Technology Employees 186
Fiscal Year-end 12 / 2026
View SEC Filings

SGHT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 5.345
Price to Book Ratio 6.634
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -9.897
Enterprise Value to Sales 4.684
Total Debt to Enterprise Value 0.113

SGHT Efficiency

Revenue/Employee 415,930.108
Income Per Employee -206,591.398
Receivables Turnover 7.939
Total Asset Turnover 0.599

SGHT Liquidity

Current Ratio 10.223
Quick Ratio 9.519
Cash Ratio 8.34

SGHT Profitability

Gross Margin 86.173
Operating Margin -47.954
Pretax Margin -49.657
Net Margin -49.67
Return on Assets -29.772
Return on Equity -50.739
Return on Total Capital -36.695
Return on Invested Capital -33.184

SGHT Capital Structure

Total Debt to Total Equity 63.769
Total Debt to Total Capital 38.938
Total Debt to Total Assets 35.364
Long-Term Debt to Equity 63.026
Long-Term Debt to Total Capital 38.485
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sight Sciences Inc - SGHT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
71.33M 81.06M 79.87M 77.36M
Sales Growth
+45.70% +13.63% -1.47% -3.13%
Cost of Goods Sold (COGS) incl D&A
12.36M 11.88M 11.58M 10.70M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.25M 614.00K 712.00K 487.00K
Depreciation
1.25M 614.00K 712.00K 487.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+43.57% -3.88% -2.53% -7.63%
Gross Income
58.97M 69.17M 68.28M 66.67M
Gross Income Growth
+46.16% +17.31% -1.29% -2.37%
Gross Profit Margin
+82.67% +85.34% +85.50% +86.17%
2022 2023 2024 2025 5-year trend
SG&A Expense
142.92M 126.45M 118.82M 103.77M
Research & Development
22.86M 17.56M 17.99M 14.61M
Other SG&A
120.06M 108.89M 100.83M 89.16M
SGA Growth
+55.65% -11.53% -6.04% -12.67%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.96M
-
EBIT after Unusual Expense
(83.95M) (57.27M) (52.49M) (37.10M)
Non Operating Income/Expense
2.23M 7.25M 5.88M 3.83M
Non-Operating Interest Income
- - 5.92M 3.97M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.47M 5.41M 4.66M 5.14M
Interest Expense Growth
+2.29% +21.09% -13.79% +10.30%
Gross Interest Expense
4.47M 5.41M 4.66M 5.14M
Interest Capitalized
- - - -
-
Pretax Income
(86.19M) (55.44M) (51.27M) (38.42M)
Pretax Income Growth
-37.31% +35.68% +7.51% +25.07%
Pretax Margin
-120.84% -68.39% -64.20% -49.66%
Income Tax
47.00K 110.00K 236.00K 10.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
47.00K 110.00K 236.00K 10.00K
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(86.24M) (55.55M) (51.51M) (38.43M)
Minority Interest Expense
- - - -
-
Net Income
(86.24M) (55.55M) (51.51M) (38.43M)
Net Income Growth
-36.98% +35.59% +7.27% +25.40%
Net Margin Growth
-120.90% -68.53% -64.49% -49.67%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(86.24M) (55.55M) (51.51M) (38.43M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(86.24M) (55.55M) (51.51M) (38.43M)
EPS (Basic)
-1.8024 -1.1423 -1.0274 -0.7369
EPS (Basic) Growth
-36.00% +36.62% +10.06% +28.28%
Basic Shares Outstanding
47.85M 48.63M 50.13M 52.15M
EPS (Diluted)
-1.8024 -1.1423 -1.0274 -0.7369
EPS (Diluted) Growth
-36.00% +36.62% +10.06% +28.28%
Diluted Shares Outstanding
47.85M 48.63M 50.13M 52.15M
EBITDA
(82.70M) (56.66M) (49.82M) (36.61M)
EBITDA Growth
-64.49% +31.49% +12.07% +26.51%
EBITDA Margin
-115.94% -69.90% -62.38% -47.32%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 10.167
Number of Ratings 8 Current Quarters Estimate -0.128
FY Report Date 12 / 2026 Current Year's Estimate -0.539
Last Quarter’s Earnings -0.14 Median PE on CY Estimate N/A
Year Ago Earnings -0.74 Next Fiscal Year Estimate -0.466
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 3 5 5
Mean Estimate -0.13 -0.10 -0.54 -0.47
High Estimates -0.08 -0.07 -0.28 -0.24
Low Estimate -0.17 -0.17 -0.67 -0.64
Coefficient of Variance -34.16 -55.93 -29.77 -41.27

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 5 5
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Sight Sciences Inc - SGHT

Date Name Shares Transaction Value
Oct 6, 2026 Paul Badawi President and CEO; Director 6,092,819 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.05 per share 55,140,011.95
Oct 6, 2026 Brenton Taylor EVP, Operations & R&D 261,990 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.85 per share 2,318,611.50
Oct 6, 2026 David Y. Badawi Chief Technology Officer; Director 1,975,075 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.05 per share 17,874,428.75
Oct 6, 2026 Alison K. Bauerlein Chief Operating Officer 639,449 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.85 per share 5,659,123.65
Oct 6, 2026 James Rodberg Chief Financial Officer 216,829 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.85 per share 1,918,936.65
Jul 8, 2026 Jeremy Hayden Chief Legal Officer 357,037 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.51 per share 1,967,273.87
Jan 8, 2026 Paul Badawi President and CEO; Director 5,925,276 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.48 per share 44,321,064.48
Jan 8, 2026 David Y. Badawi Chief Technology Officer; Director 1,920,804 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.82 per share 15,020,687.28
Jan 8, 2026 David Y. Badawi Chief Technology Officer; Director 1,917,109 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.48 per share 14,339,975.32
Jan 8, 2026 Alison K. Bauerlein Chief Operating Officer 599,983 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.48 per share 4,487,872.84
Jan 8, 2026 Jeremy Hayden Chief Legal Officer 245,420 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.48 per share 1,835,741.60
Jan 8, 2026 James Rodberg Chief Financial Officer 153,846 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.48 per share 1,150,768.08

Sight Sciences Inc in the News